Abiopharma

🔍 PATEL DHAVALKUMAR DHIRAJLAL (Executive)

Company: Sana Biotechnology, Inc. (SANA)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Acquired 125,000 shares of Common Stock (Direct)
  Date: 2026-08-26 | Code: M | equity_swap_involved: false | shares_owned_after: 224,510.00 | transaction_form_type: 4
• Sold 41,158 shares of Common Stock at $4.11 per share (Direct)
  Date: 2026-08-27 | Code: F | equity_swap_involved: false | shares_owned_after: 183,352.00 | transaction_form_type: 4
• Sold 125,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: M | equity_swap_involved: false | shares_owned_after: 250,000.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. ("Sana") common stock.
• F2: The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.